Finance
S&P 500 7,757.17 +44.60 +0.58% Dow 52,856.09 +360.21 +0.69% Nasdaq 26,702.86 +278.04 +1.05% NYSE Composite 24,253.12 +62.51 +0.26% Russell 2000 2,781.02 +7.60 +0.27% VIX 16.68 -0.63 -3.64%

PRQR · ProQR Therapeutics N.V. Ordinary Shares

NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD

ProQR Therapeutics NV (PRQR)

NASDAQ NMS - GLOBAL MARKET Biotechnology
Move probability → Options chain →
$1.36 -0.00 (-0.37%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE $1.36
$1.36 $1.42
52-WEEK RANGE $1.36
$1.30 $3.10

What's happening

Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.

Key Statistics

Market Cap$193.3M
P/E (TTM1)—
EPS2 (TTM)$-0.40
Div Yield—
Beta30.21
Volume32,179
Open1.38
Prev Close1.36
Bid / Ask1.17 / 0.00
Next Earnings 2026-11-05

Analyst Recommendations

Strong buy 6 Buy 9 Hold 1 Sell 0 Strong sell 0

Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.

Performance Overview (Trailing returns vs S&P 500 benchmark)

YTD RETURN
PRQR -31.68%
vs S&P 500 -44.46%
1-YEAR RETURN
PRQR -54.75%
vs S&P 500 -69.32%
6-MONTH RETURN
PRQR -29.23%
3-MONTH RETURN
PRQR -26.60%

Valuation Measures & Ratios

Enterprise Value4$71.6M
Forward P/E5—
PEG Ratio6-0.66
Price / Sales (TTM1)9.41
Price / Book72.77
EV4 / Revenue3.88
EV4 / EBITDA—
Profit Margin-228.18%
Operating Margin-232.60%
Return on Equity (ROE8)-75.23%
Return on Assets (ROA9)-35.80%
Avg Volume (3M)1,013,099
Glossary — what these abbreviations mean
1. TTM
Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
2. EPS
Earnings per share — net income divided by diluted shares outstanding.
3. Beta
A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
4. EV (Enterprise Value)
Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
5. Forward P/E
Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
6. PEG Ratio
P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
7. Price / Book
Share price divided by book value (assets minus liabilities) per share.
8. ROE
Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
9. ROA
Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
10. MRQ
Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
11. YoY
Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.

Short Interest

Shares Short2,866,211
Change from Prior Settlement+19.18%
% of Float—
Days to Cover (Short Ratio)4.95

Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.

Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.

Price history

Events

Drag horizontally to zoom into a section; use Reset view to restore all observations.

Technical signal summary

Calculating from the latest year of daily price history…

Calculating…
Show Technical Analysis Breakdown ▾ 10 Indicators

Not investment advice — read several signals together.

Indicators None active

Add lines over the price chart or a panel below it. Your choices are saved on this device.

Starter sets
Trend
Oscillators
Volume/volatility
Loading chart…

History limited by data provider; markers are heuristics, not signals.

Peer and sector context

No reviewed peer group is available for this symbol.

Balanced evidence

A deterministic summary of sourced facts—not an AI verdict.

Potential strengths

  • Revenue growth is 120.3% on the provider's reported measure. Finnhub fundamentals ↗
  • Latest SEC filing is Form 4, filed 2026-08-03; review it for current changes and risks. SEC EDGAR ↗

Potential concerns

Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.

No accessible free API for these — links go to the source directly.

Morningstar Motley Fool MarketBeat

Financials

Financial statement data not available for this company — SEC EDGAR XBRL coverage only includes US GAAP 10-K/10-Q filers.

Institutional holders

SEC Form 13F filers holding PRQR as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.

Institutional ownership is not available for this symbol right now.

Insider activity

Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.

Source: SEC EDGAR Form 4 filings · checked 6 most recent filings · covers 2026-06-26 to 2026-07-31

Recent transactions

  • Insiders have net bought 800,000 shares over the last 182 days, across 5 purchases and 0 sales.
  • Most recent: de Boer Daniel Anton (Chief Executive Officer) — Open market purchase of 200,000 shares on 2026-07-31.

Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.

Insider purchases & sales, last 6 months

Purchases (open market)800,000 sh(5 txns)
Sales (open market)0 sh(0 txns)
Net Shares+800,000

Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.

Insider roster

NameTitleMost Recent TransactionDateShares
de Boer Daniel AntonChief Executive OfficerOpen market purchase2026-07-31200,000
Filius BartDirectorOpen market purchase2026-07-17150,000

Recent transactions

DateInsiderTitleTransactionSharesPrice
2026-07-31de Boer Daniel AntonChief Executive OfficerOpen market purchase 200,000$1.77
2026-07-17Filius BartDirectorOpen market purchase 150,000$1.72
2026-07-09de Boer Daniel AntonChief Executive OfficerOpen market purchase 150,000$1.74
2026-07-07de Boer Daniel AntonChief Executive OfficerOpen market purchase 150,000$1.59
2026-06-26Filius BartDirectorOpen market purchase 150,000$1.54

Recent SEC filings

Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.

Source: SEC EDGAR submissions · updated 2026-10-22 02:57 UTC

FiledFormReport periodOfficial filing
2026-08-0342026-07-31 View on SEC.gov →
2026-07-2142026-07-17 View on SEC.gov →
2026-07-1342026-07-09 View on SEC.gov →
2026-07-0842026-07-07 View on SEC.gov →
2026-06-3042026-06-26 View on SEC.gov →
2026-06-0342026-06-02 View on SEC.gov →

Headlines about PRQR (ProQR Therapeutics N.V. Ordinary Shares). Links open the publisher — we don’t host full articles.

SEC filings ↓

← Back to the full dashboard · My watchlist